Naproxen Heart Risk Isolated To One Clinical Study – Bayer/Roche
This article was originally published in The Tan Sheet
Executive Summary
The NIH-funded ADAPT trial was the only postmarketing study to show naproxen users experienced a heightened number of cardiovascular events, according to an analysis of several trials by Bayer and Roche
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning